– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...
TipRanks on MSN
BMY and BNTX advance new immunotherapy bet in first-line liver cancer with ROSETTA HCC-206
Biontech Se Sponsored Adr (BNTX), Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.
Patients with hepatocellular carcinoma (HCC) achieved promising outcomes when treated with immunotherapy prior to liver transplant, a prospective study showed. Among 64 patients who received immune ...
Credit: Getty Images. The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent. The multicenter, open-label, randomized ...
LONDON (Reuters) - AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback